Macrocure, an Israeli biotech developing white blood cell injections to treat hard-to-heal wounds, raised $54 million by offering 5.4 million shares (all primary) at $10, well below the range of $13 to $15. Macrocure plans to list on the NASDAQ under the symbol MCUR. Macrocure initially filed confidentially on 5/5/2014. Credit Suisse and Jefferies & Co. acted as lead managers on the deal.
